The two growth stocks are undervalued, to be sure, but I also reveal which I think is a better investment.
2 extracted signals · 2 resolved · 0 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 01 Sept 2025, 21:45 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC

AI-generated source summary
This video compares Adobe (ADBE) and Salesforce (CRM) as long-term buy opportunities. The analyst looks into revenue growth since 2016. CRM showed a CAGR of 20.2% versus Adobe at 17.2%. Salesforce's revenue growth is attributed to acquisitions. A risk is Salesforce's willingness to overpay for acquisitions. Adobe's share price has stagnated due to artificial intelligence risks, potentially losing low-end market share due to new AI services and needs to innovate. The operation cash flow to sales is very important, it measure show much cash generate from each dollar of sales, in 2005 Adobe was 38.6% up to 42.5%. Salesforce's ratio went from 30.9% up to 34.5%. A proprietary discounted cash flow model for Salesforce shows a price of $278.88. The author says that Adobe is a "buy" for a long term investment.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
2 eligible signals linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

